Abstract. Recent research into the genetic basis and the molecular disease mechanisms of Charcot-MarieTooth disease (CMT), also called hereditary motor and sensory neuropathies, has highlighted phosphoinositides, membrane-tethered phosphorylated metabolites of phosphatidylinositol, as key regulatory molecules in peripheral nerves in health and disease. Enzymes that dephosphorylate the endosomal phosphoinositides phosphatidylinositol-3-phosphate and/ or phosphatidylinositol-3,5-biphosphate, and proteins with binding domains for these phosphoinositides, are mutated in subtypes of CMT. A hypothetical picture emerges suggesting that the precise regulation of phosphoinositide levels within neural cells, a process in turn critical for the correct dynamics of proteins binding to phosphoinositides, is a crucial bottleneck for the accurate function of myelinated peripheral nerves in both neurons and Schwann cells. The underlying molecular and cellular mechanisms are largely unknown. Some hypotheses are discussed in this essay.
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Charcot-Marie Tooth disease (CMT) denotes a heterogeneous group of genetic diseases that affect peripheral nerves, leading to pronounced muscular atrophy and weakness of distal limbs. Based on electrophysiological, neuropathological and genetic data, it is thought that the initial causative damage due to the mutation involves only the myelinating Schwann cell in some disease subtypes. In others, only motor and sensory neurons might be affected, and in some cases, both cell types may be involved (for an updated list of the genes and mutations involved in CMT, see http://www.molgen.ua.ac.be/CMTMutations/default.cfm; for detailed information on the different disease subtypes, consult http://www.neuro.-wustl.edu/neuromuscular/time/hmsn.html; for summaries of cellular and molecular disease mechanisms, see reviews [1-4]).
Delineating the initial trigger for the disease and the precise consequences at the cellular level are of utmost importance for understanding the underlying disease mechanisms and ultimately for development of promising treatment strategies. In parallel, such studies also provide considerable insights into the biology of myelinated peripheral nerves. The approximately two dozen genes identified today that lead to different forms of CMT present a rich source of proteins that are of eminent importance for the proper function of peripheral nerves. Elucidating the precise roles of these proteins and identifying potentially crucial networks in which these proteins may act in concert is a major challenge for the future. The main topic of this article, membrane-bound phosphorylated phosphatidylinositols (PI, or phosphoinositides) and their regulators and binding partners, appear to be positioned right at the heart of such a critical node of a regulatory signaling network [5] . The main cell types involved in peripheral nerves that are primarily affected by the various mutant proteins in CMT are very special cells in terms of their cell biology. This notion relates particularly to the peculiar structure of the cells and the tasks that they fulfill. Many peripheral neurons have long axonal projections that may extend up to a meter to their targets, so that these neurons face special cellular challenges with regard to building up and functionally maintaining these elaborate structures. Besides some critical basic issues of membrane and protein maintenance over long distances, general axonal transport of organelles and loaded vesicles must function efficiently in both directions during development and in homeostasis. Not surprisingly, based on the finding that distal muscles are mainly affected in CMT and supportive cell biological data, it has been suggested that deficient axonal transport may be a key issue in many forms of CMT [1] . Conversely, myelinating Schwann cells have the formidable task of producing and maintaining enormous amounts of proteins and lipids in the multi-lamellar myelin sheath. In CMT, it may still be a matter of debate how much of the disease mechanism in the individual subtypes is related to developmental alterations and how much is due to pure neural degeneration after initially normal development. Regardless of this uncertainty, which will hopefully be resolved by careful analysis of suitable animal models combined with patient data, the special challenges of Schwann cells and neurons remain. Throughout development, they have to generate bulk amounts of membranes in a highly coordinated manner. Once the cells are fully differentiated in the adult with little or no cellular turnover, both neurons and myelinating Schwann cells still have to metabolically maintain their proper structures and functions. From a cell biological point of view, another key issue in both nerve development and maintenance is ensuring accurate communication between the different cell types that critically regulates the physiology of neurons and Schwann cells in a bi-directional fashion [6, 7] . On the molecular level, the regulatory mechanisms involved include gene transcription, classical signaling pathways, membrane production, membrane and protein trafficking and function, and cytoskeletal rearrangements. Phosphoinositides have been implicated in many if not all of these crucial cellular processes [5] . Thus, it comes as little surprise given the complex cell biology of the cells involved that disturbance of the phosphoinositide metabolism is deleterious to the proper function of myelinated nerves. On the other hand, one might have expected that global alterations would not be compatible with life, given the broad role of phosphoinositides in different cell types. Is it only the complex requirements of myelinated peripheral nerves that make them particularly vulnerable, or are there also other possible explanations? To find potential answers to this question, it is instructive to have a closer look at the specific CMT-related proteins involved in phosphoinositide metabolism. One such group comprises the enzymes that dephosphorylate phosphatidylinositol-3-phosphate (PI3P) and phosphatidylinositol-3,5-biphosphate [PI(3,5)P2] [5, 8, 9] . These specific phosphoinositides are found on the cytosolic side of different categories of endosomes, and play major functional roles in the complex membrane system that regulates intracellular trafficking of membranes and proteins. PI3P is predominant on early endosomes and serves as a specific address to target proteins with PI3P-binding domains to these vesicles. There these proteins, usually in the form of larger complexes, exert their functions in various processes including membrane fusions and signaling events. PI(3,5)P2 is present in low levels in the late endosome/lysosome compartments. Its function is not well understood in mammalian cells, but might involve the control of membrane recycling between lysosomes and late endosomes. The levels of different phosphoinositides are regulated by a set of phosphoinositide kinases and phosphatases. Myotubularin-related protein (MTMR)-2 dephosphorylates both PI3P and PI(3,5)P2 specifically at the D3 position and is mutated in recessive CMT4B1 [3, 10] . MTMR2 belongs to a large family of rather ubiquitously expressed proteins. The eight family members with catalytic activity appear to share the same substrate specificity with MTMR2, and many if not all of the disease-associated MTMR2 mutations lead to loss of enzymatic activity when assayed in vitro. The six inactive members of the MTMR family tend to form complexes with active MTMRs. The most relevant interaction with regard to CMT is the formation of a tetrameric complex between MTMR2 and MTMR13, since mutations in MTMR13 are associated with recessive CMT4B2 [3, 10] . This form of the disease is pathologically indistinguishable from CMT4B1 and can be modeled in the mouse [11] . Within the MTMR2/MTMR13 complex the phosphatase activity of MTMR2 is enhanced by an order of magnitude [12] , consistent with the hypothesis that this enzymatic activity is crucial for the function of MTMR2 in myelinated peripheral nerves [13] . The regulatory situation might be more complex, however, since both MTMR2 and MTMR13 also contain protein domains that bind to phosphoinositides. In general, MTMR2 and MTMR13 are mainly cytoplasmic proteins, also in neurons and Schwann cells, but [14] . Alternatively or concomitantly, classical signaling pathways might also be altered by the changes in phosphoinositide levels and contribute to the phenotype [17] . Taken together, the available data are consistent with the hypothesis that phosphoinositides and their regulators may control myelin growth in a critical manner providing a potential key to the largely unknown molecular processes that govern how myelin membranes are added and degraded. Recently, a second active phosphoinositide phosphatase called FIG4 (or Sac3) has been identified as the culprit protein mutated in CMT4J [18, 19] . The initial observations were made in a spontaneous mouse mutant called the "pale tremor mouse", which shows a syndrome that includes widespread central (CNS) and peripheral (PNS) nervous system neurodegeneration. Of special relevance to CMT, a major loss of sensory neurons is evident during the neonatal period, while other sensory neurons contain large cytosolic vacuoles, suggesting that this stage precedes cell death. Mutant motor neurons develop morphologically similar vacuoles at the age of 6 weeks. The number of large myelinated axons is reduced, consistent with the observed neuronal alterations. Considerably slowed nerve conduction velocities indicate that alterations in myelinated Schwann cells may also be involved. The latter is supported by pathological findings in CMT4J showing, besides prominent axonal loss, thinly myelinated axons and signs of de-and remyelination. Clinically, CMT4J patients are heavily affected, also Figure 1 . The upper part of the figure shows a schematic cutaway view of a myelinated peripheral nerve fiber. Proteins known to cause CMT that are directly connected with the phosphoinositide metabolism are indicated. They are shown as being expressed in both, neurons and myelinating Schwann cells. This is an assumption based on circumstantial evidence, with the exception of MTMR2 and MTMR13, and needs to be rigorously assessed in future experiments. The exact distribution of endosomes containing PI3P and/ or PI(3,5)P2 in the myelinated neuron/axon and in the myelinating Schwann cells is also not worked out. Thus, only generic endosomes are indicated in the schema. In the lower part of the figure, the general structure of the phosphoinositide backbone is shown together with the phosphorylation sites.
Cell. Mol. Life Sci. Vol. 64, 2007 Visions & Reflections (Minireview) by profound neuronal loss in the CNS, with complex genetics. The known patients are compound-heterozygous for FIG4, each carrying a null allele in combination with a particular mutation, I41T, on the other allele. This point mutation affects FIG4 function in yeast, where it causes a partial loss of function. On the molecular level, FIG4 dephosphorylates PI(3,5)P2 at the D5 position, consistent with the observed neuronal vacuoles that are most likely of late-endosomal-lysosomal nature in the FIG4 mutant [20] . One of the critical regulatory functions of phosphoinositides is the recruitment of proteins that contain phosphoinositide-binding modules, resulting in a highly dynamic signaling system. As mentioned earlier, the culprit genes in CMT4B1 (MTMR2) and CMT4B2 (MTMR13), besides being phosphoinositide phosphatases or regulators thereof, also contain phosphoinositide-binding motifs [9] . Recent work revealed that other CMT-causing disease proteins also contain such domains. Frabin/FGD4, an actinbinding guanine nucleotide exchange factor (GEF) for the RhoGTPase Cdc42 and mutated in CMT4H, contains a FYVE domain and two PH domains, motifs known to bind to phosphoinositides [21, 22] . Intriguingly, myelin outfoldings are the hallmark of CMT4H as in CMT4B1/2, hinting towards potentially connected disease mechanisms by a crucial interplay between phosphoinositide-binding proteins and phosphoinositide modulators. Furthermore, dynamin2, a large GTPase that plays a major role in the regulation of membrane dynamics and trafficking by mediating vesicle formation, is mutated in the dominant CMTDIB in which loss of large caliber axons and myelin deficiencies are the pathological features [23] . Most interestingly, the CMTDIB-causing mutations are clustered in a phosphoinositide-binding PH domain, indicating another connection to phosphoinositides [24] . In summary, the current knowledge strongly suggests that phosphoinositide metabolism plays a key role in a variety of CMT subtypes and in peripheral nerve biology. These phospholipids seem to represent critical converging regulatory points due to the unique cellular requirements of neurons and myelinating Schwann cells. Many fine points need to be work out, such as the exact contribution of phosphoinositidemediated signaling in neurons and Schwann cells, the different forms and dynamics of the regulatory mechanisms, and the contribution and influence of other cellular mechanisms in the complex network of the physiology of the cells. This will require the elucidation of many different aspects of endosome biology with regard to endocytosis, membrane recycling, and the connected regulatory function of endosomes as critical platforms for controlling signal transduction [25] . Likely feedback mechanisms and quantitatively delicately balanced processes will have to be dissected. Novel techniques, in particular with regard to membrane dynamics of proteins and lipids, and especially phosphoinositides, will have to be developed in living cells [26] . One might argue that phosphoinositides have only been implicated in relatively rare subtypes of CMT, and that their general relevance for the more frequent causes of the disease is questionable. I would make a strong case for the theory that the proteins that are mutated in CMT play by definition a crucial role in the complex biology of peripheral nerves, and that the combined analysis of these proteins and their diseasecausing forms will eventually converge to a rather coherent picture of the critical regulatory networks involved. Knowing these networks in detail will be beneficial for the understanding of each component and the system of myelinated peripheral nerves as a whole, and in this way contribute substantially to the rational development of potential therapies for diseases affecting the nerves as an integrated unit. To leave the reader with a highly speculative thought in this regard: Altered intracellular transport, biosynthesis and/or degradation have been put forward as potential disease mechanism in some of the most common forms of CMT [2, 3, 27], in particular PMP22 duplications, which account for the majority of cases [1, 28, 29] . Many of these processes are under stringent control of phosphoinositides and their regulators as they are essential players in regulating the endosomallysosomal system and autophagy. Maybe there are more connections than obvious at first glace, both related to myelinating cells as well as to neurons and their axon.
